1, Jianfan biological (300529): according to the Ministry of Science and Technology, the Ministry of Finance, the State Administration of Taxation jointly issued the "High-tech enterprise certification management approach" and its annex "national key support for high-tech areas", the company's industry for the biomedical industry in the medical device industry.
2, Hai Zheng Pharmaceutical (600267): the company has anti-Alzheimer's varieties of patents.
3, Haisco (002653): for the pharmaceutical industry, 2016 is a year of challenges and opportunities: the strength and progress of the pharmaceutical reform exceeded expectations, from the research and development and production level of drug registration, clinical data self-checks, flight inspections, to the circulation of medicines around the pharmaceutical bidding to reduce the price of drugs, so that the pharmaceutical companies increase the cost of compliance, the growth rate of the larger challenges; but on the other hand On the other hand, the aging process of the population, the health insurance system continues to improve, the liberalization of the two-child policy, the increasing health awareness of the population, the pharmaceutical market continues to expand, bringing opportunities, hierarchical diagnosis and treatment, Internet +, precision medical plan and other policy reforms to the traditional pharmaceutical industry has brought life; along with the deepening of the industry's supply-side structural reforms, the industry's degree of concentration will be improved, which will be conducive to the long-term stable development of the entire industry. Stable development.
4, Yunnan Baiyao (000538): the pharmaceutical industry in China has been a pillar of economic growth, according to the national development plan, the 13th Five-Year Plan will maintain medium-high growth.
5, Hengrui Medicine (600276): the company is the largest research and production base of anti-tumor drugs and surgical drugs, one of the backbone enterprises of the National Torch Plan for new pharmaceutical research, development and industrialization base, "the national 863 plan results of industrialization base".
Warm reminder: the above content is for reference only, do not make any suggestions, investment risk, enter the market need to be cautious.
Answer time: 2021-05-14, the latest business changes, please refer to the official website of Ping An Bank announced shall prevail.
[Ping An Bank I know]Want to know more? Come and see "Ping An Bank I know"
/paim/iknow/index.html